Spyre Therapeutics Newsroom

Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $71

Futu NewsNov 14 10:32

Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $65

Futu NewsNov 13 20:36

Spyre Therapeutics Is Maintained at Outperform by Baird

Dow JonesNov 13 20:34

Spyre Therapeutics Analyst Ratings

BenzingaNov 13 20:24

BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $70

Futu NewsNov 13 18:31

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsNov 13 01:31

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsNov 8 22:38

TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating

Futu NewsNov 8 21:32

TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating

Futu NewsNov 8 12:32

Spyre Therapeutics Is Maintained at Buy by Guggenheim

Dow JonesOct 26 03:43

Spyre Therapeutics Analyst Ratings

BenzingaOct 26 03:32

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsOct 22 05:31

Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsOct 17 23:32

BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40

Futu NewsOct 15 18:31

Promising Advancements in Spyre Therapeutics' Programs Drive Buy Rating

TipRanksOct 15 18:19

Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40

Futu NewsOct 15 17:34

Wells Fargo Issues a Buy Rating on Spyre Therapeutics (SYRE)

TipRanksOct 15 17:10

BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40

Futu NewsSep 25 18:31

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsSep 24 20:31

Spyre Therapeutics Analyst Ratings

BenzingaSep 4 23:27